CRH Medical Corp.

CRH-T

Analysis and Opinions about CRH-T

Signal
Opinion
Expert
COMMENT
COMMENT
September 21, 2016

They continue to execute. Did a big acquisition almost 2 years ago, and now are just doing smaller incremental acquisitions that continue to build out their business. He thinks the process will continue. This has bumped up a little in valuation, and as a result it dropped down in his ranking, so he recently sold his holdings. He wouldn’t be surprised if there was an equity issue from the company in the future.

CRH Medical Corp. (CRH-T)
September 21, 2016

They continue to execute. Did a big acquisition almost 2 years ago, and now are just doing smaller incremental acquisitions that continue to build out their business. He thinks the process will continue. This has bumped up a little in valuation, and as a result it dropped down in his ranking, so he recently sold his holdings. He wouldn’t be surprised if there was an equity issue from the company in the future.

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$5.220
Owned
No
BUY WEAKNESS
BUY WEAKNESS
September 6, 2016

A good, small-cap, Canadian health care stock. A teensy bit too expensive for him right now. He likes where the business is going. Would be a buyer at the bottom of the 52-week trading range. He likes management and the board. (See Top Picks.)

CRH Medical Corp. (CRH-T)
September 6, 2016

A good, small-cap, Canadian health care stock. A teensy bit too expensive for him right now. He likes where the business is going. Would be a buyer at the bottom of the 52-week trading range. He likes management and the board. (See Top Picks.)

Alex Ruus
Portfolio Manager, Arrow Capital Management
Price
$4.750
Owned
No
COMMENT
COMMENT
September 2, 2016

This is one of the stocks that gets bucketed into the healthcare rollup. Scores well on price momentum and on valuation. Has a good balance sheet and have been growing their earnings. However, they missed on their recent quarter. If looking to play some of these “growth by acquisition” stories, this would be the one to play.

CRH Medical Corp. (CRH-T)
September 2, 2016

This is one of the stocks that gets bucketed into the healthcare rollup. Scores well on price momentum and on valuation. Has a good balance sheet and have been growing their earnings. However, they missed on their recent quarter. If looking to play some of these “growth by acquisition” stories, this would be the one to play.

Jason Mann
CIO & Co-Founder, Edgehill Patners
Price
$4.780
Owned
No
COMMENT
COMMENT
August 19, 2016

They have a product that they have been marketing and selling for some time, and are taking the cash flow from that and putting it into acquiring anaesthesiology clinics in the US. Feels this is quite undervalued given their growth prospects. They are growing their bottom line by 30% a year. He likes this a lot.

They have a product that they have been marketing and selling for some time, and are taking the cash flow from that and putting it into acquiring anaesthesiology clinics in the US. Feels this is quite undervalued given their growth prospects. They are growing their bottom line by 30% a year. He likes this a lot.

Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$4.750
Owned
Yes
BUY
BUY
August 18, 2016

He likes this whole space on a secular basis. You will have a wide disparity across the whole spectrum of stocks. We found a breakout at the beginning of August. There is support from the end of June. It made a move when it was supposed to. This stock has a nice trend. It has been in a nice band since the beginning of last year. There is some heavy duty volatility also.

He likes this whole space on a secular basis. You will have a wide disparity across the whole spectrum of stocks. We found a breakout at the beginning of August. There is support from the end of June. It made a move when it was supposed to. This stock has a nice trend. It has been in a nice band since the beginning of last year. There is some heavy duty volatility also.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$4.750
Owned
No
PAST TOP PICK
PAST TOP PICK
July 20, 2016

(A Top Pick Sept 28/15. Up 23.28%.) Not sure who is buying this, but somebody is buying quite a bit of stock. Most healthcare stocks in Canada have not done well, but this one has. He really likes management, which underpromises and overdelivers. Recently made a few acquisitions which should be accretive. Only trading at about 8.5X EBITDA with very good growth over the next couple of years.

(A Top Pick Sept 28/15. Up 23.28%.) Not sure who is buying this, but somebody is buying quite a bit of stock. Most healthcare stocks in Canada have not done well, but this one has. He really likes management, which underpromises and overdelivers. Recently made a few acquisitions which should be accretive. Only trading at about 8.5X EBITDA with very good growth over the next couple of years.

Peter Imhof
Vice President & Portfolio Manager, AGF Investments Inc
Price
$5.120
Owned
Yes
TOP PICK
TOP PICK
June 30, 2016

It has news out today. They have a consistent growth business and an acquisition business. They are making nice earnings growth. They buy a business for half what the stock trades for. They are slow and steady about it. They expanded into the US. Trading at a reasonable multiple. A year from now they will have done more acquisitions.

It has news out today. They have a consistent growth business and an acquisition business. They are making nice earnings growth. They buy a business for half what the stock trades for. They are slow and steady about it. They expanded into the US. Trading at a reasonable multiple. A year from now they will have done more acquisitions.

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$5.030
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
June 30, 2016

This has had a move at around the $4.50 level followed by a breakout. A pretty volatile stock. It looks like it wants to come back, so if you don’t own it, you will probably get your chance. If it gets about $5.10, it looks like it wants to have the $7 target. The whole space is a good place to be.

This has had a move at around the $4.50 level followed by a breakout. A pretty volatile stock. It looks like it wants to come back, so if you don’t own it, you will probably get your chance. If it gets about $5.10, it looks like it wants to have the $7 target. The whole space is a good place to be.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$5.030
Owned
Unknown
COMMENT
COMMENT
June 3, 2016

A little small for him, so he doesn’t own it. This is one of the healthcare rollup’s that has done it right. Valuation is pretty reasonable, especially one compared to some of their peers. They beat on their recent quarter, and are starting to generate cash flow. The balance sheet is in very good shape. They have managed to do acquisitions without debt, which is key for this type of business.

A little small for him, so he doesn’t own it. This is one of the healthcare rollup’s that has done it right. Valuation is pretty reasonable, especially one compared to some of their peers. They beat on their recent quarter, and are starting to generate cash flow. The balance sheet is in very good shape. They have managed to do acquisitions without debt, which is key for this type of business.

Jason Mann
CIO & Co-Founder, Edgehill Patners
Price
$4.360
Owned
No
COMMENT
COMMENT
May 19, 2016

They are in the gastro anesthesiology business. They have found a couple of pretty good niches. They are market leaders in the markets they are operating in. They are now integrating the acquisitions. Impressive management team. It is a growth stock and not a value stock. He would like to meet them, however.

They are in the gastro anesthesiology business. They have found a couple of pretty good niches. They are market leaders in the markets they are operating in. They are now integrating the acquisitions. Impressive management team. It is a growth stock and not a value stock. He would like to meet them, however.

Lorne Steinberg
President & Portfolio Manager, Lorne Steinberg Wealth Management Inc
Price
$3.880
Owned
No
PAST TOP PICK
PAST TOP PICK
May 12, 2016

(Top Pick Jun 19/15, Down 9.00%) They have done a good job. They don’t need to raise prices. 9 times earnings. They are probably looking for acquisitions. The balance sheet looks good. A premier small cap name so he continues to hold it.

(Top Pick Jun 19/15, Down 9.00%) They have done a good job. They don’t need to raise prices. 9 times earnings. They are probably looking for acquisitions. The balance sheet looks good. A premier small cap name so he continues to hold it.

Peter Imhof
Vice President & Portfolio Manager, AGF Investments Inc
Price
$3.730
Owned
Yes
WEAK BUY
WEAK BUY
April 21, 2016

A good health care services firm. This would be a Hold to a Weak Buy at this time. Really likes what they have done longer-term. If you can get this at the bottom of the 52 week trading range, that would be his Buy point. He likes management and what they are doing long term.

A good health care services firm. This would be a Hold to a Weak Buy at this time. Really likes what they have done longer-term. If you can get this at the bottom of the 52 week trading range, that would be his Buy point. He likes management and what they are doing long term.

Alex Ruus
Portfolio Manager, Arrow Capital Management
Price
$4.000
Owned
Unknown
DON'T BUY
DON'T BUY
April 7, 2016

From a seasonal perspective, you want to be looking more to the June timeframe. The chart shows a bit of resistance, and is now pulling back. There is a bit of head and shoulders topping pattern, which implies downside potential to almost $3.60. There is probably not much reason to get into this.

From a seasonal perspective, you want to be looking more to the June timeframe. The chart shows a bit of resistance, and is now pulling back. There is a bit of head and shoulders topping pattern, which implies downside potential to almost $3.60. There is probably not much reason to get into this.

Jon Vialoux
Research Analyst, CastleMoore Inc.
Price
$4.240
Owned
Unknown
COMMENT
COMMENT
April 6, 2016

He is generally negative on the rollup space, because it is a business that relies on having a high valuation in order to acquire other businesses. As soon as that game stops, the stocks can have a long way to fall before finding a bottom. This one is a little different in that they managed to not get caught up as much in the selloff. Because of that, it’s price momentum is quite good. Valuation is reasonable, which is unusual for a rollup. He doesn’t have a position in this, but it is on the cusp of being a Long for him.

He is generally negative on the rollup space, because it is a business that relies on having a high valuation in order to acquire other businesses. As soon as that game stops, the stocks can have a long way to fall before finding a bottom. This one is a little different in that they managed to not get caught up as much in the selloff. Because of that, it’s price momentum is quite good. Valuation is reasonable, which is unusual for a rollup. He doesn’t have a position in this, but it is on the cusp of being a Long for him.

Jason Mann
CIO & Co-Founder, Edgehill Patners
Price
$4.310
Owned
No
BUY WEAKNESS
BUY WEAKNESS
March 16, 2016

It is in the right space. Technically it has been a tough go for medical last year. It is one of the few sectors that is in a secular bull market. There is a downtrend that may have broken. This would be one you could add to. There will be some resistance until $5.10.

It is in the right space. Technically it has been a tough go for medical last year. It is one of the few sectors that is in a secular bull market. There is a downtrend that may have broken. This would be one you could add to. There will be some resistance until $5.10.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$4.440
Owned
Unknown
Showing 46 to 60 of 88 entries